$PPBT News

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

Why Is Purple Biotech Stock Gaining Wednesday?

Purple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models

HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17

Purple Biotech Reports Second Quarter 2026 Financial Results

CORRECTION: Purple Biotech Q2 EPS $(0.41) Beats $(0.98) Estimate

Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT)

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech Presents New Cancer Immunotherapy Data at EACR 2026, Says IM1240 Data Support First Human Study in 2027

Purple Biotech Files $200M Mixed Securities Shelf

Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights

CORRECTION: Purple Biotech Q1 EPS $(0.09) Beats $(1.06) Estimate

Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240

Purple Biotech Announces New Preclinical Data That Support The Potential Of IM1240, The Company's Lead CAPTN-3 Tri-Specific Antibody

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech Announces Formation Of Advisory Board To Support Development of Its CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform

Purple Biotech Regains Compliance with Nasdaq

Purple Biotech Regains Nasdaq Compliance